FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Larry Alphs

Research Profile

Chemicals & Drugs

Disorders

Activities & Behaviors

Procedures

Concepts & Ideas

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
Gahan Pandina; Ibrahim Turkoz; Robert Bilder; Larry Alphs
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
Larry Alphs; Cynthia A Bossie; Dong-Jing Fu; Yi-Wen Ma; Jennifer Kern Sliwa; Joseph Hulihan
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.
Larry Alphs; John Fastenau; William H Olson; Ibrahim Turkoz; Joseph F Hulihan
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Larry Alphs (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gahan Pandina; Ibrahim Turkoz; Robert Bilder; Larry Alphs
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
Schizophrenia research 2013;143(2-3):312-8.
2013: Larry Alphs; Cynthia A Bossie; Dong-Jing Fu; Yi-Wen Ma; Jennifer Kern Sliwa; Joseph Hulihan
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.
Neuropsychiatric disease and treatment 2013;9():341-50.
2012: Larry Alphs; John Fastenau; William H Olson; Ibrahim Turkoz; Joseph F Hulihan
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
The Journal of clinical psychiatry 2012;73(10):1358; author reply 1358-9.
2012: Larry Alphs; Fabrizio Benedetti; W Wolfgang Fleischhacker; John M Kane
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2012;15(7):1003-14.
2012: John J Sheehan; Dong-Jing Fu; Kristin R Reilly; Larry Alphs
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.
Innovations in clinical neuroscience 2012;9(7-8):17-23.
2012: Hugo Geerts; Patrick Roberts; Athan Spiros; Roy Twyman; Larry Alphs; Anthony A Grace
Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response.
PloS one 2012;7(12):e49732.
2012: Jennifer Kern Sliwa; Ibrahim Turkoz; Cynthia A Bossie; Dong-Jing Fu; Larry Alphs
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.
Neuropsychiatric disease and treatment 2012;8():375-85.
2012: Mahesh N Samtani; John J Sheehan; Jennifer Kern Sliwa; Dong-Jing Fu; Bart Remmerie; Larry Alphs
Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.
Clinical pharmacology : advances and applications 2012;4():25-40.
2012: Michael H Allen; Larry Alphs; John J Bartko; Carla M Canuso; David G Daniel; Dong-Jing Fu; K Jack Ishak; Dennis A Revicki; Ibrahim Turkoz; Jean-Pierre Lindenmayer
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale.
Innovations in clinical neuroscience 2012;9(1):15-24.
2011: Norris Turner; Ravi Anand; J Thomas Haskins; Sumant Khanna; Wayne Macfadden; Mark H Rapaport; Ibrahim Turkoz; Larry Alphs
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder.
Innovations in clinical neuroscience 2011;8(10):19-24.
2011: Mahesh N Samtani; Larry Alphs; Cristiana Gassmann-Mayer; Srihari Gopal; Joseph M Palumbo
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
CNS drugs 2011;25(10):829-45.
2011: Jennifer Kern Sliwa; Cynthia A Bossie; Yi-Wen Ma; Larry Alphs
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
Schizophrenia research 2011;132(1):28-34.
2011: David G Daniel; Larry Alphs; John J Bartko; Pilar Cazorla; John Panagides
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor.
Clinical schizophrenia & related psychoses 2011;5(2):87-94.
2011: Larry Alphs; Robert Morlock; Cheryl Coon; Pilar Cazorla; Armin Szegedi; John Panagides
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia.
International journal of methods in psychiatric research 2011;20(2):e31-7.
2011: Stephen R Marder; David G Daniel; Larry Alphs; A George Awad; Richard S E Keefe
Methodological issues in negative symptom trials.
Schizophrenia bulletin 2011;37(2):250-4.
2011: Larry Alphs; Srihari Gopal; Keith Karcher; Justine Kent; Jennifer Kern Sliwa; Stuart Kushner; Isaac Nuamah; Jaskaran Singh
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.
Current drug safety 2011;6(1):43-5.
2011: Wayne Macfadden; Ibrahim Turkoz; Norris Turner; Caleb M Adler; John T Haskins; Larry Alphs
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
BMC psychiatry 2011;11():171.
2011: Cynthia A Bossie; Dong-Jing Fu; Yi-Wen Ma; Jennifer K Sliwa; Larry Alphs
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
BMC psychiatry 2011;11():79.
2011: Larry Alphs; Cynthia A Bossie; Jennifer K Sliwa; Yi-Wen Ma; Norris Turner
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.
Annals of general psychiatry 2011;10(1):12.
2010: Wayne Macfadden; Yi-Wen Ma; J Thomas Haskins; Cynthia A Bossie; Larry Alphs
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia.
Psychiatry (Edgmont (Pa. : Township)) 2010;7(11):23-31.
2010: Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
Journal of affective disorders 2010;126(3):358-65.
2010: Larry Alphs; Robert Morlock; Cheryl Coon; Arjen van Willigenburg; John Panagides
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training.
Psychiatry (Edgmont (Pa. : Township)) 2010;7(7):26-32.
2010: Carla M Canuso; Augusto Grinspan; Amir Kalali; ChandrasekharRao Venkata Damaraju; Ursula Merriman; Larry Alphs; A George Awad
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
International clinical psychopharmacology 2010;25(3):155-64.
2010: Aaron S Kemp; Nina R Schooler; Amir H Kalali; Larry Alphs; Ravi Anand; George Awad; Michael Davidson; Sanjay Dubé; Larry Ereshefsky; Georges Gharabawi; Andrew C Leon; Jean-Pierre Lepine; Steven G Potkin; An Vermeulen
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
Schizophrenia bulletin 2010;36(3):504-9.
2010: John M Kane; Michael Cohen; Jun Zhao; Larry Alphs; John Panagides
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Journal of clinical psychopharmacology 2010;30(2):106-15.
2010: Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Journal of affective disorders 2010;122(1-2):27-38.
2010: J Thomas Haskins; Wayne Macfadden; Norris Turner; Concetta Crivera; Riad Dirani; Larry Alphs; Kenneth Gersing; Bruce Burchett
Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions.
Journal of medical economics 2010;13(3):552-8.
2009: Wayne Macfadden; Larry Alphs; J Thomas Haskins; Norris Turner; Ibrahim Turkoz; Cynthia Bossie; Mary Kujawa; Ramy Mahmoud
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
Bipolar disorders 2009;11(8):827-39.
2009: Ira D Glick; Cynthia A Bossie; Larry Alphs; Carla M Canuso
Onset and persistence of antipsychotic response in patients with schizophrenia.
Journal of clinical psychopharmacology 2009;29(6):542-7.
2009: Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
Asenapine versus olanzapine in acute mania: a double-blind extension study.
Bipolar disorders 2009;11(8):815-26.
2009: Roger S McIntyre; Miriam Cohen; Jun Zhao; Larry Alphs; Thomas A Macek; John Panagides
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
Bipolar disorders 2009;11(7):673-86.
2009: Dawn I Velligan; Larry Alphs; Scott Lancaster; Robert Morlock; Jim Mintz
Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia.
Psychiatry research 2009;169(2):97-100.
2007: Alan Breier; Larry Alphs; Brendon Binneman
Wayne Fenton's impact on industry.
Schizophrenia bulletin 2007;33(5):1154-5.
2007: Cathryn Clary; Antony Loebel; Ilise Lombardo; Larry Alphs; Brendon Binneman; Douglas Vanderburg; Lewis Warrington; Bruce Parsons; Ilan Fogel; Barry Herman; Holly Roberts; Hilda Templeton; Diana Hughes; Phillip Chappell; Douglas E Feltner; Kathy Tobias; Eric Watsky; Tanya Ramey; Fred Rappard
Comments on "Presidential address: advocacy as leadership".
The American journal of psychiatry 2007;164(2):346; author reply 346.
2007: Larry Alphs; John Panagides; Scott Lancaster
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
Psychopharmacology bulletin 2007;40(2):41-53.
2007: Craig H Mallinckrodt; Christy Chuang-Stein; Paul McSorley; Jeffrey Schwartz; Donald G Archibald; David Perahia; Michael Detke; Larry Alphs
A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant.
Pharmaceutical statistics 2007;6(1):9-22.
2007: A Carlo Altamura; Emanuela Mundo; Roberta Bassetti; A Green; Jean-Pierre Lindenmayer; Larry Alphs; Herbert Y Meltzer
Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder.
Schizophrenia research 2007;89(1-3):140-6.
2006: Larry Alphs
An industry perspective on the NIMH consensus statement on negative symptoms.
Schizophrenia bulletin 2006;32(2):225-30.
2004: Marc Bourgeois; Joel D Swendsen; Frederick Young; Xavier F Amador; Stefano Pini; Giovanni B Cassano; Jean-Pierre Lindenmayer; Chuanchieh Hsu; Larry Alphs; Herbert Y Meltzer
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial.
The American journal of psychiatry 2004;161(8):1494-6.
2004: Larry Alphs; Ravi Anand; M Zahur Islam; Herbert Y Meltzer; John M Kane; Ranga Krishnan; Alan I Green; Steven G Potkin; Guy Chouinard; Jean-Pierre Lindenmayer; Rob Kerwin
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.
Schizophrenia bulletin 2004;30(3):577-86.
2003: Jean-Pierre Lindenmayer; Pal Czobor; Larry Alphs; Ann-Marie Nathan; Ravi Anand; Zahur Islam; James C-Y Chou
The InterSePT scale for suicidal thinking reliability and validity.
Schizophrenia research 2003;63(1-2):161-70.
2003: Steven G Potkin; Larry Alphs; Chuanchieh Hsu; K Ranga Rama Krishnan; Ravi Anand; Frederick K Young; Herbert Y Meltzer; Alan Green
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
Biological psychiatry 2003;54(4):444-52.
2003: Herbert Y Meltzer; Larry Alphs; Alan I Green; A Carlo Altamura; Ravi Anand; Alberto Bertoldi; Marc Bourgeois; Guy Chouinard; M Zahur Islam; John M Kane; Ranga Krishnan; Jean-Pierre Lindenmayer; Steven G Potkin
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Archives of general psychiatry 2003;60(1):82-91.
2003: Steven G Potkin; Ravi Anand; Larry Alphs; Kirsten Fleming
Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide.
Schizophrenia research 2003;59(1):59-66.